No. The public hospital program in India (Ayushman Bharat, Government hospital subsidies) can be availed of only by Indian citizens. Foreigners will have to avail themselves of the private hospital route, wherein service fees are charged. Divinheal offers quotations before travel commitment.

No. Under THOTA and NOTTO (National Organ and Tissue Transplant Organisation) rules, deceased donor organs go only to Indian nationals on the national waiting list. International patients must bring an approved living donor. There are no exceptions to this rule.

The surgery is done under general anaesthesia. After surgery, pain at the incision site is well-managed with scheduled pain relief. Most patients say the first 2–3 days are the most uncomfortable, and this eases to a manageable level by day 5. A working transplanted kidney does not cause ongoing pain. The most commonly reported discomfort in the early weeks is soreness at the incision and a slightly full feeling in the lower abdomen — both ease as healing progresses.

Several Indian hospitals report excellent kidney transplant outcomes. Among Divinheal partner hospitals, Apollo Hospitals Chennai is one of India’s highest-volume transplant centres. It performs 300+ kidney transplants each year, including ABO-incompatible cases. Medanta – The Medicity Gurgaon’s Institute of Kidney and Urology is one of the country’s top transplant programmes. Laparoscopic donor nephrectomy is standard practice there. Fortis Memorial Research Institute, Gurgaon, has a dedicated transplant ICU and strong outcomes data. For government hospitals (not Divinheal partners): SGPGI Lucknow and CMC Vellore are nationally recognised for transplant volume and results.

In JCI/NABH certified hospitals in India, one-year graft survival after kidney transplantation from a living donor is 90-95%; five-year graft survival is 75-85%. One-year survival of the patient ranges between 95-98%, while five-year survival is between 85-92%. These statistics conform to internationally accepted standards of SRTR (US) and ERA-EDTA (Europe). For deceased donor transplantation, these numbers are slightly less (one-year graft survival 85-90%) but are not available to international patients in India.

Yes, for patients who meet the legal criteria — an available living related donor and clinical eligibility for transplant. India’s high-volume JCI-accredited centres deliver outcomes matching Western hospitals at 60–80% lower cost. The legal and ethical rules are strict — this protects against organ trafficking and keeps donors safe. For Oman patients, India’s closeness and cultural familiarity make it the practical first choice. For UK patients, India’s timeline (4–8 weeks vs a 3–4 year NHS wait) is the main reason to consider it.

Living donor kidney transplant: ₹8,00,000-₹16,00,000 ($9,600-$19,300) for a standard ABO compatible transplant. ABO incompatible transplant: ₹ 10,00,000-20,00,000 ($ 12,000-24,000). Monthly immunosuppressants: ₹13,500-39,000 a month (generic brands, $160–470 a month). Accommodation and food costs (6 weeks in India): Total costs would be around ₹1,20,000-₹3,00,000 ($1,450-$3,600) depending on the apartment standard.

Your immune system sees the new kidney as genetically different and tries to destroy it — mainly through T-cells targeting HLA (human leukocyte antigen) differences between donor and recipient. Modern triple immunosuppression (Tacrolimus, Mycophenolate Mofetil, Prednisolone) is designed to block these immune responses while keeping enough immunity to fight infection. Regular Tacrolimus blood level checks keep the drug at the exact strength needed to prevent rejection without causing too much toxicity.

Side effects fall into two groups: surgical and medicine-related. Surgical side effects include wound infection, hernia, and bleeding — all managed during the hospital stay. Medicine-related side effects come from long-term immunosuppression. The main long-term side effects of immunosuppression are: • Higher risk of infection, especially in the first year when doses are highest • Higher risk of certain cancers (skin cancer, lymphoma) — requires annual checks • High blood pressure — Tacrolimus raises blood pressure in many patients • Kidney toxicity at high Tacrolimus levels • New-onset diabetes after transplant (NODAT) — occurs in 10–20% of recipients on steroid and Tacrolimus therapy. Most side effects can be managed with monitoring and dose changes.

Yes. Freedom from dialysis — the most disruptive daily burden of ESRD — transforms life for most recipients. Patients return to work, travel, hobbies, and family life. The main ongoing commitments are: • Twice-daily medicine (no exceptions) • Blood tests (monthly initially, then tapering off) • Yearly cancer screening Among these, most kidney transplant recipients feel a quality of life significantly higher than when they were on dialysis.

About 6 weeks total: Time required to go through pre-transplant screening and legal formalities (1-2 weeks), hospital stay (post-surgery) for 2 weeks, followed by 2 weeks of outpatient observation before travelling. In case there are any issues post-transplant, like delayed graft function or rejection, the time will increase. However, this is an estimated time frame. Divinheal provides the flexibility of extending the contract for serviced apartments without penalty.

Contact a Divinheal coordinator via the website, email, or phone. Share your most recent kidney function tests, a brief medical summary, and your intended donor’s blood group. Within 5–7 working days, you will receive written recommendations from two or three partner transplant hospitals, along with itemised cost estimates in OMR or GBP. A teleconsultation with the transplant specialist is arranged before any travel commitment is made.